United Homes Group stock plunges after Nikki Haley, directors resign
NEW YORK - The Nasdaq Stock Market announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:APLM) and warrants (NASDAQ:APLMW) on Wednesday. The stock has shown remarkable momentum, posting a 227% return over the past six months, though InvestingPro data indicates high price volatility.
Trading in the company’s shares will restart at 9:00 a.m. Eastern Time on October 15, 2025, while warrants will resume trading five minutes later at 9:05 a.m., according to a statement released Tuesday.
The announcement comes after a month-long trading halt that began on September 17, 2025, when trading was suspended at 2:37 p.m. Eastern Time. Nasdaq did not provide specific reasons for the original suspension or the decision to resume trading.
Apollomics is a clinical-stage biopharmaceutical company that develops cancer therapeutics.
The Nasdaq Stock Market, operated by Nasdaq Inc. (NASDAQ:NDAQ), regularly implements trading halts for various regulatory reasons, including pending news announcements, regulatory concerns, or technical issues.
The information was disclosed in a press release issued by Nasdaq.
In other recent news, Apollomics Inc. has announced the termination of all its U.S. employees, which includes key executives such as Chief Executive Officer Dr. Guo-Liang Yu and Chief Financial Officer Dr. Matthew Plunkett. This decision is attributed to the company’s current cash position. Additionally, Apollomics has indicated plans to discontinue all activities related to its SPARTA clinical trial at the earliest opportunity. The company is also planning a shareholder vote on winding up, signaling a potential significant shift in its operations. These developments highlight a period of considerable change for Apollomics as it navigates its financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.